EGFR and non-small cell lung carcinoma: Although immune checkpoint inhibitors (ICIs) show limited overall efficacy, heterogeneity in response by programmed cell death ligand 1 (PD-L1) expression exists.<h4>Methods</h4>We retrospectively evaluated 90 patients with advanced/recurrent EGFRm NSCLC treated with first-line EGFR-TKIs (October 2018-October 2023).